What is BPC-157?

BPC-157 is a pentadecapeptide composed of 15 amino acids. It is a fragment of the body protection compound (BPC) protein complex, originally identified in human gastric juice.

In preclinical studies, BPC-157 has been the subject of significant scientific interest due to its potential role in the processes of muscle, tendon, ligament, and other connective tissue repair. In laboratory models, activity related to organ protective mechanisms and the gastric mucosa has also been described.

In the context of the gastrointestinal system, effects have been observed in models of increased intestinal permeability, inflammatory processes, gastrointestinal spasms, and experimental ulcerations. In separate experimental models, a potential analgesic effect has also been reported.

Under laboratory conditions, BPC-157 is associated with processes such as increased collagen and reticulin formation, as well as angiogenesis. Concurrently, macrophage and fibroblast activity has been observed, placing it among compounds investigated in relation to tissue regeneration.

Observations on BPC-157

BPC-157 is considered in scientific literature in connection with the following potential areas of action:

• Injury Healing – observations on tendons, muscles, joints, and bone tissue have been described.

• Chronic Inflammatory Processes – a potential role in limiting the inflammatory response is being considered.

• Gastrointestinal Protection – support for the mucosa and reduction of ulcerative lesions have been observed.

• Circulation – effects on angiogenesis and local blood supply have been described.

• Surgical Recovery – accelerated tissue regeneration has been observed under experimental conditions.

• Organ Protection – beneficial effects on liver, heart, and nerve tissue have been described in in vivo models.

• Joint and Bone Health – effects on cartilage structure and bone repair have been observed.

• Anti-inflammatory Mechanisms – potential for limiting local inflammatory reactions is being investigated.

• Recovery after exertion – faster recovery after physical stress has been described in experimental models.

Administration and Dosage

In scientific literature, subcutaneous administration once daily is most commonly described. The experimental doses used typically range between 250–500 μg (0.25–0.5 mg) daily.

When dissolving 5 mg with 3 ml of bacteriostatic water:

The resulting concentration is 1.67 mg/ml, which means that 0.15 ml contains approximately 0.25 mg = 250 μg.

Example values for 5 mg:

0.15 ml = 250 μg

0.3 ml = 500 μg

0.45 ml = 750 μg

0.6 ml = 1 mg

0.75 ml = 1.25 mg

When dissolving 10 mg with 3 ml of bacteriostatic water:

The resulting concentration is 3.33 mg/ml, which means that 0.15 ml contains approximately 0.5 mg = 500 μg.

Example values for 10 mg:

0.15 ml = 500 μg

0.3 ml = 1 mg

0.45 ml = 1.5 mg

0.6 ml = 2 mg

0.75 ml = 2.5 mg

Scientific Data

BPC-157 has been primarily investigated in preclinical models, where a wide range of potential physiological effects have been observed.

In an orthopedic context, observations have been described for accelerated recovery of tendons, ligaments, and muscles, as well as stimulation of osteogenesis in bone injuries.

In gastroenterological models, effects on the gastric and intestinal mucosa have been observed, including reduction of ulcerative lesions, recovery from experimental colitis, and reduction of damage associated with non-steroidal anti-inflammatory drugs.

In cardiological experimental models, protective effects against ischemic myocardial damage have been described, as well as improvements related to angiogenesis and local blood supply.

Neurological models consider a potential role in supporting peripheral nerve regeneration and limiting neurotoxic damage.

Additionally, anti-inflammatory effects have been observed in experimental models of arthritis, including reduction of pain and local edema.

Application in Sports

BPC-157 is included in the WADA prohibited list for professional sports, as effects related to:

• accelerated tissue recovery after physical exertion

• influence on tendons, joints, and connective tissue

• effect on tissue regeneration processes

• improved adaptation to intense physical exertion

Possible Side Effects

In preclinical conditions, BPC-157 is described as well-tolerated. Reported reactions are rare, usually mild, and more frequently associated with higher doses.

Described reactions include:

• mild stomach discomfort or nausea

• redness or sensitivity at the application site

This information has been compiled and systematized from various scientific publications and studies. It serves an educational purpose only and should not be used for the diagnosis, treatment, or prevention of diseases.